Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the... (GlobeNewswire EN) +++ SCYNEXIS Aktie +25,36%

KODIAK SCIENCES Aktie

 >KODIAK SCIENCES Aktienkurs 
45.58 EUR    +60.6%    (TradegateBSX)
Ask: 47.75 EUR / 300 Stück
Bid: 46.55 EUR / 300 Stück
Tagesumsatz: 1915 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
Aktie über LYNX handeln
>KODIAK SCIENCES Performance
1 Woche: -0,4%
1 Monat: -16,3%
3 Monate: -6,4%
6 Monate: +42,7%
1 Jahr: +101,8%
laufendes Jahr: +12,2%
>KODIAK SCIENCES Aktie
Name:  KODIAK SCIENCES DL-,0001
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US50015M1099 / A2N6P0
Symbol/ Ticker:  K27 (Frankfurt) / KOD (NASDAQ)
Kürzel:  FRA:K27, ETR:K27, K27:GR, NASDAQ:KOD
Index:  -
Webseite:  https://kodiak.com/
Profil:  Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases. The company works on treatments for conditions that affect the retina and can lead to vision loss, with a portfolio centered on o..
>Volltext..
Marktkapitalisierung:  1784.84 Mio. EUR
Unternehmenswert:  1808.32 Mio. EUR
Umsatz:  -
EBITDA:  -193.86 Mio. EUR
Nettogewinn:  -212.44 Mio. EUR
Gewinn je Aktie:  -3.68 EUR
Schulden:  134.1 Mio. EUR
Liquide Mittel:  110.52 Mio. EUR
Operativer Cashflow:  -139.14 Mio. EUR
Bargeldquote:  2.39
Umsatzwachstum:  -
Gewinnwachstum:  -24.91%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  KODIAK SCIENCES
Letzte Datenerhebung:  28.09.26
>Kennzahlen
Aktien/ Unternehmen:
Aktien: 62.85 Mio. St.
Frei handelbar: 92.54%
Rückkaufquote: -8.93%
Mitarbeiter: 124
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Strong buy
Kursziel: 96.65%
Bewertung:
KGV: -
KGV lG: -
KUV: -
KBV: 33.58
PEG-Ratio: -0.71
EV/EBITDA: -
Rentabilität:
Bruttomarge: -
Gewinnmarge: -
Operative Marge: -
Managementeffizenz:
Gesamtkaprendite: -94.25%
Eigenkaprendite: -368.37%
>Peer Group
Gesundheit, Antikörper- Behandlung, Augenmedizin/ Sehhilfen
 
28.09.26 - 12:48
Kodiak Sciences: Aktie springt nach Studienerfolg um über 30 % (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
26.09.26 - 00:12
Kodiak Sciences to Present Topline Results on September 28, 2026 from DAYBREAK Pivotal Phase 3 Study of Zenkuda and KSI-501 in Patients with Wet Age-Related Macular Degeneration (PR Newswire)
 
Kodiak Sciences to Host Webcast on Monday, September 28 at 8:30 AM Eastern Time PALO ALTO, Calif., Sept. 25, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing......
23.09.26 - 16:00
The Zacks Analyst Blog Highlights Kodiak Sciences, Celldex Therapeutics, Rapport Therapeutics and Vaxcyte (Zacks)
 
Four biotech companies face key fall readouts that could influence the development and commercial prospects of their pipelines....
13.08.26 - 22:03
Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2026 Financial Results (PR Newswire)
 
PALO ALTO, Calif., Aug. 13, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2026. "Kodiak continues to execute broadly across our late-stage clinical portfolio as we approach......
10.08.26 - 22:45
Kodiak Sciences Announces First Patients Enrolled in Global Phase 3 ALTO trial of KSI-501 in Patients with Diabetic Macular Edema (PR Newswire)
 
Phase 3 ALTO trial designed to demonstrate superiority of KSI-501 versus aflibercept in patients with diabetic macular edema PALO ALTO, Calif., Aug. 10, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching,......
06.08.26 - 13:06
Kodiak Sciences Completes Enrollment in First Pivotal Cohort in the Phase 3 PEAK Trial of KSI-101 for Macular Edema Secondary to Inflammation and Reaffirms Topline Clinical Data Release Remains on Track for December 2026 (PR Newswire)
 
First pivotal cohort enrolled 300 subjects, with topline clinical data from 24-week primary endpoint on track for December 2026 release Completion of enrollment in the second pivotal cohort evaluating 600 subjects across the PEAK and PINNACLE studies is expected in 4Q 2026, with topline......
06.06.26 - 03:01
Insiderhandel: Chief Financial Officer verkauft Aktien von Kodiak Sciences im Wert von 1023009 USD (Insiderkauf)
 
Borgeson, John A. - Vorstand - Tag der Transaktion: 2026-06-04...
29.05.26 - 00:12
Kodiak Sciences to Present at 2026 Jefferies Global Healthcare Conference (PR Newswire)
 
PALO ALTO, Calif., May 28, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina-focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced that Victor Perlroth, M.D., Chief Executive......
17.05.26 - 22:24
Why One Healthcare Fund Increased Its Kodiak Sciences Stake Amid an Eye-Popping Rally (Fool)
 
This clinical-stage biotech develops innovative retinal disease therapies, with its lead candidate advancing through late-stage trials....
07.05.26 - 23:21
Kodiak Sciences GAAP EPS of -$0.94 beats by $0.07 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
07.05.26 - 22:03
Kodiak Sciences Announces Recent Business Highlights and First Quarter 2026 Financial Results (PR Newswire)
 
PALO ALTO, Calif., May 7, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the third quarter ended March 31, 2026. "Kodiak has entered 2026 with continued momentum and increasing clarity as we advance toward key......
01.05.26 - 06:27
Kodiak Sciences to Present Pipeline Advances and KSI-101 Clinical Data, Including Results from a MESI Cohort in a Tertiary Care Uveitis Practice, at Upcoming Scientific Conferences (PR Newswire)
 
Clinical results of KSI-101 in macular edema secondary to inflammation (MESI) from a tertiary care uveitis practice demonstrate outcomes consistent with results from the U.S. Phase 1b APEX study, supporting continued global development and expansion of the Phase 3 PEAK and PINNACLE......
05.04.26 - 01:01
Insiderhandel: Chief Financial Officer verkauft Aktien von Kodiak Sciences im Wert von 1197488 USD (Insiderkauf)
 
Borgeson, John A. - Vorstand - Tag der Transaktion: 2026-04-02...
31.03.26 - 22:54
Kodiak Sciences GAAP EPS of -$1.04 in-line (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
31.03.26 - 22:48
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results (PR Newswire)
 
PALO ALTO, Calif., March 31, 2026 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2025. "Kodiak's momentum has continued to build, highlighted by positive Phase 3......
27.03.26 - 18:45
KOD Stock Soars on Promising Phase III Data for Eye Disease Candidate (Zacks)
 
Kodiak Sciences rallies 75% as phase III GLOW2 data show Zenkuda's strong efficacy, safety and risk reduction in diabetic retinopathy patients....
27.03.26 - 03:18
Meta, Kodiak Sciences, Unity Software, Lumentum Holdings And Reddit: Why These 5 Stocks Are On Investors′ Radars Today (Benzinga)
 
Major U.S. indices closed lower, with the Dow Jones Industrial Average declining 1.01% to 45,960.11. Importance Rank:  1 read more...
26.03.26 - 15:45
Olaplex, Kodiak Sciences, Precigen And Other Big Stocks Moving Higher On Thursday (Benzinga)
 
Olaplex Holdings shares surge 51% after being acquired by Henkel AG & Co. KGaA. Other big gainers include Kodiak Sciences Inc and Precigen Inc. Importance Rank:  1 read more...
26.03.26 - 13:30
Jefferies Financial, MillerKnoll dip premarket; Kodiak Sciences surges (Investing.com)
 
Um den gesamten Artikel unter investing.com zu lesen, klicken Sie bitte auf die Überschrift...
26.03.26 - 12:18
Kodiak Sciences: Aktie legt nach positiven Studienergebnissen kräftig zu (Investing.com DE)
 
Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Respekt vor den Fakten. Gefühl für das Wichtige. Kraft zur Unabhängigkeit. - Nomen Nescio
>Aktienauflistung | >Aktienscreener | >Aktienkennzahlen | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!